UROXATRAL Drug Patent Profile
✉ Email this page to a colleague
When do Uroxatral patents expire, and when can generic versions of Uroxatral launch?
Uroxatral is a drug marketed by Concordia and is included in one NDA.
The generic ingredient in UROXATRAL is alfuzosin hydrochloride. There are nineteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the alfuzosin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Uroxatral
A generic version of UROXATRAL was approved as alfuzosin hydrochloride by APOTEX INC on July 18th, 2011.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for UROXATRAL?
- What are the global sales for UROXATRAL?
- What is Average Wholesale Price for UROXATRAL?
Summary for UROXATRAL
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 104 |
Clinical Trials: | 4 |
Patent Applications: | 267 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for UROXATRAL |
Drug Sales Revenues: | Drug sales revenues for UROXATRAL |
What excipients (inactive ingredients) are in UROXATRAL? | UROXATRAL excipients list |
DailyMed Link: | UROXATRAL at DailyMed |
![UROXATRAL drug patent expirations Drug patent expirations by year for UROXATRAL](/p/graph/s/t/UROXATRAL-patent-expirations.png)
![Drug Prices for UROXATRAL](/p/graph/drug-price/UROXATRAL.png)
![Drug Sales Revenue Trends for UROXATRAL](/p/graph/drug-sales-revenues/UROXATRAL.png)
Recent Clinical Trials for UROXATRAL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University Hospitals Cleveland Medical Center | N/A |
Sanofi | N/A |
University of Pennsylvania | Phase 3 |
Pharmacology for UROXATRAL
Drug Class | alpha-Adrenergic Blocker |
Mechanism of Action | Adrenergic alpha-Antagonists |
Paragraph IV (Patent) Challenges for UROXATRAL
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
UROXATRAL | Extended-release Tablets | alfuzosin hydrochloride | 10 mg | 021287 | 9 | 2007-06-12 |
US Patents and Regulatory Information for UROXATRAL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Concordia | UROXATRAL | alfuzosin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021287-001 | Jun 12, 2003 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for UROXATRAL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Concordia | UROXATRAL | alfuzosin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021287-001 | Jun 12, 2003 | ⤷ Sign Up | ⤷ Sign Up |
Concordia | UROXATRAL | alfuzosin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021287-001 | Jun 12, 2003 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for UROXATRAL
See the table below for patents covering UROXATRAL around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Israel | 128146 | THREE LAYERED TABLET WITH CONTROLLED RELEASE OF ALFUZOSIN HYDROCHLORIDE | ⤷ Sign Up |
Slovakia | 284388 | ⤷ Sign Up | |
South Africa | 9707766 | ⤷ Sign Up | |
China | 100335057 | ⤷ Sign Up | |
African Regional IP Organization (ARIPO) | 9901470 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |